Orion Oyj (OTCMKTS:ORINY - Get Free Report) reached a new 52-week high on Wednesday . The stock traded as high as $35.12 and last traded at $35.12, with a volume of 146 shares traded. The stock had previously closed at $33.52.
Orion Oyj Price Performance
The company has a 50-day moving average of $30.43 and a two-hundred day moving average of $27.26. The stock has a market capitalization of $10.08 billion, a PE ratio of 28.35 and a beta of 0.17. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.42 and a quick ratio of 1.41.
Orion Oyj (OTCMKTS:ORINY - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The company reported $0.23 EPS for the quarter. Orion Oyj had a return on equity of 39.49% and a net margin of 23.01%. The company had revenue of $373.03 million for the quarter. Sell-side analysts predict that Orion Oyj will post 1.18 EPS for the current fiscal year.
Orion Oyj Increases Dividend
The company also recently announced a dividend, which was paid on Tuesday, April 29th. Stockholders of record on Monday, April 7th were given a $0.4478 dividend. This is a positive change from Orion Oyj's previous dividend of $0.24. The ex-dividend date of this dividend was Monday, April 7th. Orion Oyj's dividend payout ratio (DPR) is presently 24.43%.
Orion Oyj Company Profile
(
Get Free Report)
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.
Featured Articles
Before you consider Orion Oyj, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Orion Oyj wasn't on the list.
While Orion Oyj currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
